|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CDH17 expression in gastric cancer specimens was evaluated by immunohistochemistry.
|
31605356 |
2020 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings offer new insights into the mechanism of the CDH17/NF-κB/MMP-2 axis, and the associated signalling pathways might represent novel targets for the treatment of GC.
|
29783070 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling.
|
31095636 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-expression of CDH17 gene can significantly improve apoptosis-inducing effects of cisplatin in vitro and in vivo, which is a new strategy to improve chemotherapeutic effects on gastric cancer.
|
29203930 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results of the present study suggest that CDH17 may be a promising candidate for the therapeutic targeting of gastric cancer.
|
27909714 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer.
|
28453457 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The co-expression of HOXA13 and CDH17 was analyzed in the gastric cancer patient cohort in TCGA database using cBioportal and UCSC Xena.
|
28387908 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
|
27580354 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our data firstly demonstrate the capacity of CDH17 to regulate the activity of Ras/Raf/MEK/ERK pathway for cell proliferation in GC, and suggest that CDH17 can serve as an attractive therapeutic target for future research.
|
24465527 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to further identify the role of CDH17 in the tumorigenesis and lymphatic metastasis of GC.
|
23298905 |
2013 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CDH17 was consistently up-regulated in human gastric cancers, and overall survival in patients with CDH17 upregulation was poorer than in those without expression of this gene (5 yrs overall survival rate 29.0% vs. 45.0%, P<0.01).
|
23554857 |
2013 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data establish a foundation for future studies of the comprehensive protein expression patterns and effects of CDH17 in GC.
|
22791949 |
2012 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that, in addition to the known intestinal transcription factor caudal type homeobox 2, EGFR activation induces LI-cadherin expression and participates in intestinal differentiation of GC.
|
22676223 |
2012 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using an in vivo tumor growth assay, we confirmed that CDH17 silencing could obviously slow the growth of gastric cancer derived from BGC823 cells.
|
20500517 |
2010 |